The Dual-Use Dilemma: Is Using Both Cigarettes and Vapes Better or Worse Than Just Smoking?

The smoker who vapes in the office and smokes on the weekend. The smoker who switched to vaping but still has a cigarette with morning coffee. The smoker who alternates between vaping and smoking throughout the day, reducing cigarette consumption from twenty to five but never reaching zero. These patterns—'dual use' of combustible cigarettes and electronic cigarettes—are among the most common, and among the most controversial, in the nicotine landscape. An estimated 30-40% of vapers in the US and UK continue to smoke at least occasionally. The public health community is divided on what this means. One camp views dual use as harm reduction: any reduction in cigarette consumption, even if incomplete, reduces exposure to combustion products and therefore reduces disease risk. The other camp views dual use as a failure: the goal is complete smoking cessation, and dual use represents a state of continued risk that may delay or prevent the achievement of that goal.

The toxicological evidence supports both positions, depending on the metric. Dual users who have substantially reduced their cigarette consumption show significantly lower levels of tobacco-specific biomarkers—cotinine, NNAL (a tobacco-specific nitrosamine metabolite), carbon monoxide, and volatile organic compounds—compared to exclusive smokers. The reduction is roughly proportional to the reduction in cigarette consumption: a dual user who smokes five cigarettes per day instead of twenty has approximately 75% less exposure to combustion-derived toxicants. This is, by any measure, a substantial health improvement. But the dose-response relationship between cigarette consumption and disease risk is nonlinear—a smoker who reduces from twenty to five cigarettes per day does not achieve 75% of the health benefits of complete cessation, because even low levels of smoke exposure carry disproportionate cardiovascular risk. The dual user who has cut down but not quit is healthier than the exclusive smoker—but not as healthy as the exclusive vaper, and nowhere near as healthy as the person who has quit all nicotine.

The behavioral trajectory of dual use is the key question. If dual use is a transitional state—a stepping stone on the path from smoking to vaping to complete smoking cessation—then it represents progress, and the public health goal should be to support dual users in completing the transition. If dual use is a stable endpoint—a permanent pattern of reduced but not eliminated smoking—then it represents a missed opportunity for the additional health gains of complete cessation, and the public health goal should be to encourage dual users to stop smoking entirely. The evidence on trajectories is mixed and highly context-dependent. Longitudinal studies find that a significant proportion of dual users do eventually quit smoking completely—typically within 12-24 months of initiating dual use—but a proportion remain dual users indefinitely, particularly those who use vaping for situations where smoking is not permitted (work, indoor environments) while maintaining cigarette use for situations where smoking is preferred (social settings, with alcohol). The trajectory depends on the individual's motivation, the product characteristics (nicotine delivery, satisfaction), and the social and environmental context. Dual use is not a single behavior with a single outcome. It's a category that contains multiple trajectories, and the public health response needs to be correspondingly nuanced.

The regulatory implications are significant. Policies that restrict access to vaping products—flavor bans, high taxation, PMTA requirements that limit product availability—may have the unintended effect of pushing dual users back toward exclusive smoking. If a dual user's preferred vaping product is removed from the market, and the alternatives are less satisfying, the most likely behavioral response is not complete cessation—it's increased cigarette consumption. The flavor ban studies from San Francisco and Massachusetts, which found increases in smoking following flavor restrictions, are consistent with this mechanism: dual users who could no longer access the flavored vaping products that made dual use sustainable reverted to the cigarettes they had been trying to reduce. The regulatory calculus—is it better to restrict vaping products to prevent youth initiation, even if doing so reduces the options available to dual users trying to quit smoking?—is not a simple tradeoff. It involves balancing the uncertain future risk of youth nicotine initiation against the certain present risk of adult smoking relapse. The evidence suggests that the adult-smoking side of the equation deserves more weight than current regulatory frameworks give it.

For the individual smoker trying to navigate the dual-use dilemma, the evidence supports a pragmatic, goal-oriented approach. If dual use is a step toward complete smoking cessation, it is unequivocally beneficial—reducing cigarette consumption by any amount reduces disease risk, and the eventual goal of zero cigarettes remains achievable. If dual use has become a stable pattern, with no movement toward complete cessation, the smoker should evaluate whether a different product (higher nicotine delivery, different form factor) might support the final transition, or whether additional behavioral support (counseling, quitline, digital cessation program) could help bridge the gap. The clinical approach to dual use should be supportive and non-judgmental: acknowledge the progress already made (reducing cigarette consumption is genuinely difficult), identify the barriers to complete cessation (what situations trigger the remaining cigarettes?), and develop a plan for addressing those barriers. The message should not be 'dual use is failure.' It should be 'dual use is a step—what would it take to take the next one?'

The dual-use dilemma illuminates a broader tension in public health: the tension between harm reduction (which accepts incremental progress) and abstinence (which demands complete cessation). Both have value. Neither is always right. The smoker who has reduced from twenty cigarettes to five, and who maintains that reduction for years, has achieved a genuine health improvement—not as large as complete cessation, but real and worth acknowledging. The public health community that can celebrate that improvement while encouraging further progress is more likely to retain the trust and engagement of the smoker it is trying to help. The public health community that treats dual use as equivalent to smoking—a position that some advocacy organizations explicitly endorse—is not just scientifically inaccurate. It's alienating the very people it claims to serve.

Shareable insight: Dual use—smoking and vaping at the same time—is not a stable category. For some, it's a stepping stone to quitting. For others, it's a permanent compromise. The evidence is clear: any reduction in smoking is better than no reduction. The goal is to help dual users take the next step, not to dismiss the step they've already taken.